Yamazaki Hideya, Inoue Takehiro, Yoshida Ken, Yoshioka Yasuo, Furukawa Souhei, Kakimoto Naoya, Shimizutani Kimishige
Department of Radiology, National Hospital Organization Osaka National Hospital, Hoenzaka 2-1-14 Chuo-ku, Osaka city, Osaka 540-0006 Japan.
Anticancer Res. 2007 Jan-Feb;27(1B):491-7.
To examine the efficacy of major radioactive sources used in brachytherapy and the influence of age.
Six hundred and forty-eight patients with node negative oral tongue cancer (T1-3NOMO; 212T1, 352T2, 84T3) treated at Osaka University Hospital, between 1967 and 1999, were reviewed.
The 5-year local control rates for patients treated with Ra-226 and Ir-192 were 85%, and 79% for Ti, 75% and 73% for T2, 62% and 64% for T3 tumors, respectively, and for those in the MicroSelectron-high-dose-rate (MS-HDR) group were 87% for T1, 79% for T2 and 89% for T3. Patients 65 years of age or older attained lower 5-year local control rates (67% for total cases; 72% for Ti, 68% for T2 and 59% for T3) than their younger counterparts (79%, 86%, 77% and 69%; p=0.004).
The three major radioactive sources produced results that were not significantly different, and age proved to be a factor influencing outcomes.
研究近距离放射治疗中主要放射源的疗效及年龄的影响。
回顾了1967年至1999年间在大阪大学医院接受治疗的648例口腔舌癌患者（T1 - 3N0M0；212例T1，352例T2，84例T3），这些患者均无淋巴结转移。
接受镭 - 226和铱 - 192治疗的患者5年局部控制率分别为85%，T1肿瘤为79%，T2肿瘤为75%和73%，T3肿瘤为62%和64%；在微型选择高剂量率（MS - HDR）组中，T1肿瘤为87%，T2肿瘤为79%，T3肿瘤为89%。65岁及以上患者的5年局部控制率（所有病例为67%；T1为72%，T2为68%，T3为59%）低于年轻患者（分别为79%、86%、77%和69%；p = 0.004）。
三种主要放射源产生的结果无显著差异，年龄被证明是影响治疗结果的一个因素。
Zotero 插件